Resumen

GONZALEZ YIBIRIN, M  y  BARRETO SEACHOQUE, B. Evaluación del Diklason^® ampollas en el dolor agudo. AVFT [online]. 2010, vol.29, n.1, pp.6-9. ISSN 0798-0264.

Background: Acute pain is defined as a pain of recent onset and probably limited duration which is associated with a causal and temporal damage or disease. NSAIDs modulate peripheral pain by reducing prostaglandin and neuropeptides production. Typical examples of acute pain include post operatory, lumbago, bone or soft tissue injuries and, renal colic. This type of pain is increased by anxiety, catastropic events, neuroticism and depression. Diclofenac potassium is proved to be safe and effective in management acute pain. Materials and methods: We conducted a multicenter; prospective, open study in 220 patients with acute pain (moderate to severe intensity) which supply with IM or IV dose of diclofenac potassium (Diklason^®) 75 mg, the pain intensity was measured by the following scales: VAS 0-100, PID, SPID, Pain Relief and TOTPAR, rescue medication and clinical scale changes. The safety was assessed by direct questioning side effects. Evaluations were performed at baseline at 30 minutes, 1, 2, 4, 6, 8, and 12 hours after dosage. Results: There was a significant decrease in VAS levels from 30 minutes of treatment and this decrease was significant between the evaluation periods up to 8 hours, the effect persisted for 12 hours. In 90.45% of patients began to feel pain relief within 30 minutes. All scales evaluated showed significant changes in the periods evaluated from the first 30 minutes up to 8 hours (SPID), 12 h (SPID, PR, and TOTPAR). In 92.72% of results were suitable: excellent (56.3%) and good (36.36%). We found 6 mild adverse effects. Conclusions: Diclofenac potassium (Diklason^®) is quick, effective and durable in the management of acute pain of various etiologies.

Palabras clave : Diclofenac; acute pain; VAS.